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Cardiac fibroblasts (CFs) play critical roles in heart development, homeostasis, and disease.
The limited availability of human CFs from native heart impedes investigations of CF biology
and their role in disease. Human pluripotent stem cells (hPSCs) provide a highly renewable
and genetically defined cell source, but efficient methods to generate CFs from hPSCs have
not been described. Here, we show differentiation of hPSCs using sequential modulation of
Wnt and FGF signaling to generate second heart field progenitors that efficiently give rise to
hPSC-CFs. The hPSC-CFs resemble native heart CFs in cell morphology, proliferation, gene
expression, fibroblast marker expression, production of extracellular matrix and myofibroblast
transformation induced by TGFβ1 and angiotensin II. Furthermore, hPSC-CFs exhibit a more
embryonic phenotype when compared to fetal and adult primary human CFs. Co-culture of
hPSC-CFs with hPSC-derived cardiomyocytes distinctly alters the electrophysiological
properties of the cardiomyocytes compared to co-culture with dermal fibroblasts. The hPSC-
CFs provide a powerful cell source for research, drug discovery, precision medicine, and
therapeutic applications in cardiac regeneration.
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Cardiac fibroblasts (CFs) compromise a significant fractionof cells in the heart estimated using lineage tracing to beabout 15% of the nonmyocyte cells in mouse heart1, and
CFs contribute to heart function, homeostasis, and structure in
multiple ways. The production and remodeling of extracellular
matrix (ECM) are the best known functions of CFs. Secretion of
growth factors and complex mixtures of regulatory molecules in
extracellular vesicles provide another important way that CFs
regulate cardiac function. During development, signaling from
CFs is necessary to stimulate cardiomyocyte proliferation2. CFs
are intimately involved in many of the dysregulated signaling
pathways linked to heart disease such as β-adrenergic signaling in
heart failure3. Activated CFs and resulting pathological fibrosis
can lead to impaired mechanical function associated with heart
failure as well as abnormal electrical activity linked to arrhyth-
mias and sudden cardiac death4. Not surprisingly, with this range
of cardiac-specific effects, evidence has emerged that CFs are
tissue-specific cells distinct from other fibroblasts in the body5.
Given the role of CFs in cardiac biology and disease, investi-
gators have isolated and studied primary CFs from surplus
patient material obtained at the time of cardiac surgery, cardiac
biopsy, or autopsy. However, disease- and patient-specific cardiac
tissue samples are not always available. For example, many
patients with inherited heart disease typically do not undergo
cardiac surgical interventions. Thus, a robust, reproducible, and
patient-specific source of CFs is desirable. Because human plur-
ipotent stem cells (hPSCs) can renew indefinitely in culture,
hPSCs provide an unlimited source of genetically identical hPSC-
CFs in contrast to primary tissue sources of CFs. Prior studies
have identified fibroblasts as a low-abundance cell type present
following protocols optimized to differentiate hPSCs to cardio-
myocytes (hPSC-CMs)6,7. In addition, recent investigations have
defined protocols to generate epicardial cells from hPSCs that
subsequently can be differentiated into CFs8–11. However, effi-
cient differentiation of hPSCs to well characterized CFs has not
been described.
During embryonic development, CFs arise from multiple
sources. The epicardium is considered the major source of CFs
found in the ventricular myocardium12–16 with epicardial cells
undergoing an epithelial-to-mesenchymal transition requiring
expression of Tcf21 to generate CFs12,13,17,18. Lineage tracing
with the epicardial marker, Tbx18, demonstrated Tbx18-expres-
sing fibroblasts compromised only one-third of the CFs in
embryonic and adult heart13; however, a more recent investiga-
tion with a Wt1-Cre mouse showed up to 80% of CFs in the adult
heart were derived from the epicardium19. Another significant
population of CFs is derived from the endocardium at the time of
endocardial cushion formation by an endothelial-to-
mesenchymal transition19,20, and endocardial cells are gener-
ated in part from the second heart field progenitors (SHFPs)21.
Lastly, a small fraction of fibroblasts are derived from neural crest
lineages22.
In the present study, we develop a protocol to generate hPSC-
CFs via SHFPs using sequential inhibition of GSK3β to activate
canonical Wnt signaling followed by stimulation with bFGF. The
differentiated hPSC-CFs exhibit cell morphology, growth, gene
expression, fibroblast markers, ECM production, and myofibro-
blast transformation similar to native human CFs.
Results
Progenitors arise during cardiac differentiation of hPSCs.
Biphasic modulation of the Wnt signaling pathway with small
molecules is sufficient to direct the differentiation of monolayer
cultured hPSCs to CMs23,24. Activation of canonical Wnt sig-
naling by GSK3β inhibition stimulates hPSCs to sequentially form
mesoderm and cardiac progenitors that are subsequently induced
to differentiate to CMs by inhibition of Wnt signaling. We first
determined the stage-specific mesodermal and cardiac progenitor
populations generated by this small molecule (GiWi) protocol
(Fig. 1a). Flow cytometry demonstrated that the early meso-
dermal marker Brachyury (Bry) was expressed in almost all cells
after 24 h of treatment with CHIR. Expression of Bry was present
for another 24 h before it was downregulated after day 2 (Fig. 1b,
Supplementary Fig. 1a). CD90 was robustly expressed in hPSCs,
but its expression gradually declined during the differentiation.
Most of the cells expressed CD90 at days 2–3 (>80%), but the
expression level of CD90 was lower than in hPSCs (Fig. 1b,
Supplementary Fig. 1b). This Brydown/CD90low progenitor stage
at day 2–3 first showed upregulation of MESP1 and GATA4
mRNA expression which are expressed in cardiac mesodermal
progenitors (Fig. 1c), followed by the upregulation of cardiac
transcription factors ISL1, NKX2-5, and TBX5 indicating com-
mitment of cardiac progenitors in the GiWi protocol (Fig. 1c).
The apelin receptor (APLNR) is expressed in mesodermal pro-
genitors including lateral plate mesodermal cells specified to
be cardiac progenitors as well as APLNR+ cells that have
the potential to give rise to mesenchymal stem cells (MSCs)
and endothelial cells25–28. APLNR expression was first seen at
day 3, and APLNR+ cells peaked at 66% of the cells on day 4
and then rapidly declined (Fig. 1b, Supplementary Fig. 1c).
KDR+/PDGFRα+ cells have been identified as cardiac progenitor
cells (CPCs) that can be differentiated mainly to CMs in the
cardiac differentiation of hPSCs6. We found the KDR+/PDGFRα+
CPCs were mainly generated on day 4–5 (Fig. 1b, Supplementary
Fig. 1d). These stage-specific progenitors were reproducibly gen-
erated from other hPSC lines using the GiWi protocol (Supple-
mentary Fig. 2).
FGF promotes differentiation of SHFPs and CFs. Because prior
studies have demonstrated that fibroblast growth factor (FGF)
signaling contributes to the generation of cardiac mesodermal
progenitors and exerts a dominant effect over BMP signaling
directing cardiac mesodermal progenitors to nonmyocyte
fates29,30, we tested the impact of FGF signaling on the stage-
specific progenitors present in the GiWi protocol to promote
differentiation of CFs rather than CMs (Fig. 2a). We examined a
range of concentrations of bFGF (0–125 ng/ml) added at different
cardiac progenitor stages in a defined medium (CFBM, Supple-
mentary Table 1) for fibroblast differentiation. Following 20 days
of differentiation, cells were analyzed by flow cytometry using a
specific fibroblast antibody (mouse anti-human fibroblast, clone
TE-731) and an antibody to sarcomeric myosin (MF20) expressed
in CMs (Fig. 2b, Supplementary Fig. 3). Changing the medium
and adding bFGF on day 2 or day 3 effectively prevented the
generation of MF20+ CMs, and there was a concentration-
dependent increase in fibroblast marker positive cells, which
peaked at 75 ng/ml bFGF added on day 2 of differentiation
(Fig. 2b). Higher concentrations of bFGF, when added on day 3
or day 4, resulted in significant cell death after day 6 of differ-
entiation and no cells survived to 20 days (Fig. 2b). Applying a
fixed concentration of 75 ng/ml of bFGF to cardiac mesodermal
progenitors in a context-dependent fashion generated large
population of fibroblasts from multiple hPSC lines which we refer
to as hPSC-CFs (Fig. 2c).
We focused our effort on the protocol adding 75 ng/ml of
bFGF in CFBM medium starting on day 2 following GSK3β
inhibition (Gi) which we describe as the GiFGF protocol
(Protocol I in Fig. 2a). To understand the impact of bFGF on
the differentiation of day 2 cardiac mesodermal progenitors in the
GiFGF protocol, we examined the temporal gene-expression
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pattern for developmentally regulated transcription factors and
associated genes using quantitative real time polymerase chain
reaction (qRT-PCR) (Fig. 3a, Supplementary Fig. 4). The early
mesodermal gene T was transiently upregulated after the GSK3β
inhibitor (CHIR) treatment peaking at day 1. MESP1 and GATA4
started to express on day 2 of differentiation following the
expression of T, indicating the formation of cardiac mesodermal
progenitors (Fig. 3a). Next, the cardiac-related transcription
factors were upregulated following bFGF treatment including
ISL1, TBX1, GATA4, NKX2-5, HAND2 (Fig. 3a, Supplementary
Fig. 4). The expression of ISL1, GATA4, and HAND2 remained
high through 20 days of differentiation. Interestingly, the pattern
of expression is consistent with the formation of SHFPs given the
prominent expression of ISL1, TBX1, GATA4, and HAND2
(Fig. 3b)32–36. The results are also consistent with the demon-
strated role of FGF signaling driving differentiation of pharyngeal
mesoderm to SHFPs37. These results contrast the cardiomyocyte-
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Fig. 1 Identification of progenitors in cardiac differentiation of hPSCs. a Schematic method for the small molecule protocol using GSK3β inhibition with CHIR
followed by Wnt inhibition with IWP (GiWi protocol) to efficiently differentiate hPSCs to cardiomyocytes (CMs) and the associated markers for stage-
specific progenitors. b Flow cytometry of stage-specific progenitors labeled by Brachyury (Bry), CD90, Apelin receptor (APLNR), KDR, and PDGFRα in early
differentiation (day 0–5) of the GiWi protocol. No primary antibody controls and isotype controls were performed for each time point, and the day 0, no
primary antibody control (Neg ctrl) is shown as an example. c qRT-PCR showing the expression of relevant mesodermal and cardiac-related transcription
factors in the progenitor stages of the GiWi protocol (day 0–6, n= 3 technical replicates). TBX5, d1 expression was not detectable. Data are mean ± SEM.
The data are from DF19-9-11T hiPSC line
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associated with first heart field (FHF) progenitors including
TBX538, HAND1, and TBX20 are more prominently expressed
(Fig. 3b). In addition, the ion channel gene, HCN4, which is
recognized as the FHF progenitor marker39, was minimally
expressed in the GiFGF protocol compared to the GiWi protocol
(Fig. 3b). Furthermore, the cardiac transcription factors ISL1,
NKX2-5, and GATA4, which are expressed in both FHF and SHF,
were differentially expressed in the GiFGF and GiWi protocols
(Fig. 3b). Particularly, ISL1 expression persisted longer in GiFGF
protocol compared to an early peak in expression in the GiWi
protocol on day 4 then declining. In contrast, NKX2–5 expression
peaked early in the GiFGF protocol at day 6 and rapidly
downregulated after day 10 compared to the GiWi protocol where
NKX2-5 expression increased after day 10 and is greatest at day
20. TCF21, a bHLH transcription factor required for the
formation of CF in mouse heart18, was progressively upregulated
from day 6–20 in the GiFGF protocol (Fig. 3a, Supplementary
Fig. 4). However, we did not observe a significant upregulation of
(pro)epicardial genes such as TBX18 and WT1 with the FGF
directed CF differentiation (Fig. 3a, Supplementary Fig. 4),
consistent with the findings that FGF signaling inhibits (pro)
epicardium differentiation from the cardiac mesoderm29. We also
examined the EMT markers of SNAI1 and SNAI2 in the GiFGF
protocol and found an early upregulation of SNAI1 (day 2–3) and
a late upregulation of SNAI2 (day 6–20) (Fig. 3a). THY1 (CD90)
expression was high in the undifferentiated hPSCs but down-
regulated during CF differentiation (Fig. 3c). Given that high
bFGF concentrations can be supportive of maintenance of
pluripotency of hPSCs, we examined the expression of the
pluripotency gene OCT4 and showed it to be completely
downregulated during the CF differentiation (Fig. 3c), similar to
the downregulation observed in cardiomyocyte differentiation
protocols7,23,40,41. Finally, we examined the cell lineage-specific
gene-expression pattern. VIM, commonly expressed in fibro-
blasts, was greatly upregulated during CF differentiation in
contrast to TNNT2, a cardiomyocyte-specific gene, which is
minimally expressed in the GiFGF protocol (Fig. 3d). Further-
more, POSTN, a gene expressed in CFs42, was also greatly
upregulated by 20 days differentiation in the GiFGF protocol,
whereas the general fibroblast-associated DDR2 gene showed a
smaller fold change compared to POSTN (Fig. 3d). To screen for
gene expression typical of endothelial or smooth muscle cells, we
examined PECAM1 (CD31) and MYH11 (smooth muscle myosin
heavy chain) expression and found there was very low expression
of PECAM1 and essentially no expression of MYH11 in the
GiFGF protocol (Fig. 3d).
Based on the gene-expression data showing SHF genes were
significantly upregulated upon bFGF addition in the GiFGF
protocol, we used flow cytometry to examine the temporal
expression of Islet1 and the recently identified SHF marker
CXCR4 (CD184)43 in the GiFGF protocol compared to the GiWi
protocol (Fig. 4a, Supplementary Fig. 5). Islet1 expressing cells first
were detected on Day 3 of both protocols, but bFGF signaling
resulted in the majority of cells being Islet1 positive in the GiFGF
protocol relative to a smaller fraction in the GiWi protocol during
the progenitors stages (Day 3–5). Furthermore, Islet1/CXCR4
double positive cells were the majority of cells (69%) on Day 5 in
the GiFGF protocol and were only scarcely detected in the GiWi
protocol. After 20 days of differentiation, we evaluated for the
different cell lineages present and confirmed the GiWi protocol
gives rise to predominantly hPSC-CMs (MF20+) and the GiFGF
protocol gives rise to predominantly hPSC-CFs (fibroblast TE-7+)
with a small population of smooth muscle cells (SM-MHC+)
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Fig. 2 Effect of bFGF on hPSC-derived mesodermal and cardiac progenitors. a Schematic for testing the concentration-dependent effect of bFGF addition to
stage-specific progenitors generated by the GiWi protocol beginning bFGF on day 2, 3, or 4, corresponding to labeled protocols I, II, and III. Gray lines
indicate RPMI medium+B27 without insulin supplement; blue lines indicate cardiac fibroblast basal medium (CFBM); green lines indicate CHIR treatment;
red lines indicate bFGF treatment; orange line indicates IWP treatment. b Flow cytometry analysis of day 20 differentiated cells from protocols I, II, III
labeled by human fibroblast marker (clone TE-7 antibody) and cardiomyocyte marker (MF20 antibody for sarcomeric myosin). c Average percentage of
fibroblast population differentiated from hESC line H1 (n= 7, biological replicates) and hiPSC line DF19-9-11T (n= 14, biological replicates) at 20 days. Data
are mean ± SEM
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CD31+ endothelial cells were detected under these conditions
(Fig. 4b, Supplementary Fig. 6).
We sought to further define the lineage hierarchy of the hPSC-
CFs by evaluating for expression of a marker associated with
vascular endothelial progenitors, Tie244, and the endocardial-
specific transcription factor during early cardiac development,
NFATc145. We also examined the time course of expression of
Islet1 as endocardial populations have been described from Islet1-
positive and -negative populations in the developing mouse
heart21. Despite the persistent expression of Islet1 detected from
day 4 to day 20 in the GiFGF protocol, no significant Tie2-
positive cells were observed (Fig. 4c, Supplementary Fig. 7).
Evaluation for NFATc1 expression from day 10 to day 20 also
showed no significant population of NFATc1-positive cells
(Supplementary Fig. 8). A time course of the generation of
hPSC-CFs during the GiFGF protocol shows the appearance of
TE-7+ cells starting on day 6 and increasing in abundance to day
18 consistent with the generation of hPSC-CFs from Islet1/
CXCR4 double positive SHFPs (Fig. 4d). In summary, the GiFGF
protocol generates an enriched pool of SHFPs that give rise to
hPSC-CFs without going through an evident endocardial
progenitor cell stage (Fig. 4e).
Comparison of hPSC-CFs, primary CFs, and dermal fibro-
blasts. We next compared the properties of hPSC-CFs with
commercially available primary human fetal ventricular CFs
(hfV-CFs) and adult ventricular CFs (haV-CFs), and adult dermal
fibroblasts (hDFs). The morphology of hPSC-CFs, hfV-CFs, and
haV-CFs maintained in similar media was comparable with
spindle-shaped and polygonal cells present, but distinct from
hDFs which were larger, flatter and more irregular in shape
(Fig. 5a). The hPSC-CFs and hfV-CFs were more proliferative
than haV-CFs and can propagate for more than 14 passages,
while haV-CFs could only grow ~9 passages before undergoing
senescence (Fig. 5b). The expression of CD90 (THY1), which has
been used as a cell surface marker for some fibroblast popula-
tions, was uniformly expressed on hDFs and maintained over
multiple passages. In contrast, expression of CD90 was present on
only a fraction of hPSC-CFs, hfV-CFs and haV-CFs (~30%) and
was present on a progressively smaller percentage of cells with
passaging. Notably, the hPSC-CFs, hfV-CFs, and haV-CFs
showed a similar change in expression of CD90 over passages
(Fig. 5c, Supplementary Fig. 9). The hDFs were uniformly positive
(~100%) for the intracellular fibroblast marker (clone TE-7)
during passaging, and the hPSC-CFs, hfV-CFs, and haV-CFs
showed that 80–90% of the cells were positive at early passage.
The TE-7-positive cells increased to 99% with subsequent pas-
saging and then declined as the CFs approached senescence
(Fig. 5c Supplementary Fig. 10).
We tested labeling vimentin, an intermediate filament protein
expressed in fibroblasts, and show that all of the clone TE-7
fibroblast antibody labeled cells from hPSC-CFs, hfV-CFs, haV-
CFs, and hDFs populations also uniformly expressed vimentin,
whereas hPSC-CMs did not express vimentin (Fig. 6a, Supple-
mentary Figs. 11 and 12). The surface markers of PDGFRα
(CD140a) and PDGFRβ (CD140b) have been reported to label a
portion of primary mouse and human CFs5, and so we also
examined their expression in hPSC-CFs, hfV-CFs, haV-CFs,
hDFs, and hPSC-CMs by flow cytometry. PDGFRα was expressed
in more than 90% of the cells in all the fibroblast populations, but
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Fig. 3 Analysis of cardiogenic gene expression during GiFGF protocol. a qRT-PCR showing the expression and hierarchy of transcription factors in the time
course of the GiFGF protocol (day 0–20). b qRT-PCR showing the expression patterns of the transcription factors in FHF and SHF in the GiFGF protocol in
comparison with the GiWi protocol. c qRT-PCR showing the expression time course of CD90 and OCT4 in GiFGF protocol (day 0–20). d qRT-PCR showing
the expression of markers for fibroblasts (VIM, POSTN, and DDR2), cardiomyocytes (TNNT2), and nonmyocyte lineages (PECAM1 and MYH11) in the time
course of the GiFGF protocol (day 0–20). The qRT-PCR time course data are from consecutive samples from the same differentiation round with n= 3
technical replicates for each point. Data are mean ± SEM. The data are from DF19-9-11T hiPSC line
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also expressed in the majority of the hPSC-CFs and hfV-CFs, as
wells as hDFs (90%), but with a relatively lower percentage (62%)
in haV-CFs. A very small population of PDGFRβ+ cells which
may represent nonmyocytes in the hPSC-CMs preparation
(Fig. 6b). Immunolabeling of the cell preparations was performed
to evaluate for other proteins associated with fibroblasts. The
transcription factor GATA4 has previously been reported to be
expressed in CFs but not in DFs5, and we found the TE-7-labeled
fibroblasts from hPSC-CFs, hfV-CFs, and haV-CFs were all
GATA4 positive in contrast to hDFs which showed no
immunolabeling for GATA4. hPSC-CMs were negative for the
fibroblast marker TE-7, but positive for GATA4 (Fig. 6c). There
were no cTnT+ cells detected in any of the fibroblast cell lines,
but hPSC-CMs preparation showed abundant cTnT+ cells
(Fig. 6c). Periostin is a matricellular protein associated with
fibroblasts that is expressed in mouse CFs during embryonic
development and downregulated in adult mouse CFs except
following injury42,46. Furthermore, a recent study demonstrated
that periostin is expressed in CFs differentiated from hPSC-
derived epicardial cells9. Because periostin is a secreted protein,
flow cytometry is problematic for detection of expressing cells, so
we performed Q-PCR to examine POSTN expression. All of the
fibroblast populations examined expressed POSTN, but hPSC-
CM did not show expression (Fig. 6d). Immunolabeling for FSP1,
another protein associated with fibroblasts, was detected in the
majority of cells from all fibroblast cell lines and likewise, the
ECM proteins collagen I and fibronectin were expressed across all
the fibroblast preparations (Supplementary Fig. 14). Thus, while
hPSC-CFs share some properties with hDFs, they are most
similar to hfV-CFs and haV-CFs in their morphology and marker
expression, particularly in the pattern of expression of CD90 and
GATA4.
Gene expression of hPSC-CFs is most similar to primary CFs.
To characterize the gene-expression pattern in hPSC-CFs, we
performed RNA-seq on hPSC-CFs and compared the total
mRNA transcripts with those of haV-CFs, hDFs, hPSC-CMs, and
hPSCs. Analysis of gene expression across all the samples showed
the greatest similarity in the abundance of overall transcripts
(19,084) between hPSC-CFs and primary haV-CFs calculated by
Euclidean distance (Fig. 7a). Bioinfomatics analysis using the
online tool AmiGO2 for cardiac-related genes (58) demonstrated
cardiac factors were enriched in hPSC-CFs, haV-CFs, and hPSC-
CMs with hPSC-CFs and haV-CFs showing the greatest similarity
(Fig. 7b). For example, BMP4, GATA4, and SOX17 were similarly
expressed in hPSC-CFs and haV-CFs, but not expressed in hDFs.
However, other key cardiac genes showed greater expression in
hPSC-CFs compared to haV-CFs, including HAND2, HEY1, ISL1,
and NKX2-5 (Fig. 7b). We also analyzed the ECM-related gene
expression in all samples given the role of ECM production in
fibroblast biology. High expression of collagens (COL1A1,
COL1A2, COL3A1, COL5A1, COL5A2, COL6A1, COL6A2,
COL6A3, COL8A1, and COL12A1), fibronectin (FN1), the matrix
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Fig. 4 Evaluation of progenitors and cardiovascular lineages in CF and CM differentiation. a Flow cytometry analysis of cells on day 0–6 in the GiFGF and
GiWi protocols for FHF/SHF marker Islet1 and SHF marker CXCR4. For day 0–2, the protocols are identical, diverging on day 3. b Flow cytometry analysis
of the day 20 differentiated cells from the GiFGF and GiWi protocols for fibroblasts (anti-human fibroblasts, clone TE-7), CMs (MF20), smooth muscle
cells (SM-MHC), and endothelial cells (CD31). c Flow cytometry analysis of cells throughout the GiFGF protocol for expression of Islet1 and the endothelial
progenitor marker, Tie2. d Flow cytometry analysis of cells throughout the GiFGF protocol for expression of the fibroblast marker (anti-human fibroblasts,
clone TE-7). e Schematic method of the GiFGF protocol and stage-specific progenitors in differentiation of hPSCs to CFs. Gray lines indicate RPMI medium
+B27 without insulin supplement; blue lines indicate cardiac fibroblast basal medium (CFBM); green lines indicate CHIR treatment; red lines indicate bFGF
treatment. MP mesodermal progenitor, CMP cardiac mesodermal progenitor, SHFP second heart field progenitor, CF cardiac fibroblast. The data are from
DF19-9-11T hiPSC line
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and tissue inhibitor of metalloproteinases 1, 2, and 3 (TIMP1,
TIMP2, and TIMP3) were seen in all fibroblasts (Fig. 7c). How-
ever, some of the genes, including COL4A1, COL4A2, COL4A5,
and COL18A1 were more highly expressed in hPSC-CFs and
haV-CFs than hDFs, and MMP3 was expressed only in hDFs.
Cluster analysis for the overall ECM-related gene expression
again demonstrated hPSC-CFs and haV-CFs were the most clo-
sely related cell populations studied (Fig. 7c).
To compare the hPSC-CFs and haV-CFs in more detail, we
performed gene ontology (GO) analysis using the online Functional
Annotation Tool (DAVID Bioinformatics Resources 6.7, NIAID/
NIH) for the differentially expressed genes (Fig. 7d, Supplementary
Data 1 and 2). Genes classified as extracellular region or extracellular
region part are highly enriched in both hPSC-CFs and haV-CFs.
Genes involved in membrane proteins are enriched in hPSC-CFs,
whereas genes involved in cell–cell and cell–ECM attachment are
enriched in haV-CFs. Interestingly, genes involved in pattern
specification process, anterior/posterior pattern formation, and
embryonic morphogenesis are enriched in hPSC-CFs consistent with
the hPSC-CFs being more embryonic in phenotype (Fig. 7d).
To further examine the identity of hPSC-CFs, we compared
our RNA-seq data with a recent publication which performed
RNA-seq for gene-expression analysis of primary human fetal
and adult CFs47. Unsupervised cluster analysis of ten repre-
sentative genes differentially expressed in human fetal and adult
CFs identified by Jonsson et al.47, demonstrated that hPSC-CF
cluster most closely with hfV-CFs relative to the haV-CFs
(Supplementary Fig. 15a). Furthermore, unsupervised cluster
analysis of the cardiac factors (58 genes) showed the most
similarity between the two haV-CFs, then grouped with the
hfV-CFs and hPSC-CFs subsequently. The key cardiac factors
expressed in hPSC-CFs that we identified above including
BMP4, GATA4, SOX17, HAND2, HEY1, ISL1, and NKX2-5
(Fig. 7b) are all expressed in hfV-CFs. Furthermore, HEY1,
ISL1, and NKX2-5 showed higher expression in hfV-CFs than
in haV-CFs in the Jonsson et al. study47, similar to the
expression pattern in hPSC-CFs relative to haV-CFs in our
data, consistent with a more embryonic phenotype of the hPSC-
CFs (Supplementary Fig. 15b, Data 1). Interestingly, the
transcription factor TBX20 has been identified in adult mouse
and human CFs as a key marker5, but TBX20 is expressed to
significantly lower level in fetal human CFs47. Our data also
showed TBX20 expression is significantly lower in hPSC-CFs
(Supplementary Data 2), consistent with a more embryonic
phenotype of the hPSC-CFs. ECM gene expression was similar
across all the samples (Supplementary Fig. 15c). In summary,
these gene-expression data demonstrate hPSC-CFs are most
closely related to human native CFs relative to the other cell
types studied, and the gene expression pattern is consistent with
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Fig. 5 Comparison of CF and DF in morphology, proliferation and marker expression. a Phase contrast images of hPSC-CFs, hfV-CFs, haV-CFs, and hDFs.
b Growth capacity of hPSC-CF, hfV-CF, and haV-CF during sequential passaging. c CD90 and the human fibroblast maker (clone TE-7) expression
examined by flow cytometry in hPSC-CFs, hfV-CF, haV-CFs, and hDFs during passaging. Scale bars are 400 μm. The hPSC-CFs are from hiPSC line DF-19-
9-11T. The primary hfV-CFs are from Cell Applications, Inc. The haV-CFs are from Lonza, NHCF-V. The hDF line is from skin biopsies from healthy donor
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hPSC-CFs produce 3D ECM scaffold. Generation of ECM is a
major function of CFs. Therefore, we examined the ECM
generated by the hPSC-CFs in comparison with the hfV-CFs,
haV-CF, and hDFs following 10 days of high-density cul-
ture48. To examine the ECM production and assembly, the
fibroblast cultures were fixed, but not permeabilized, and
immunolabeled with the antibodies to collagen type I and
fibronectin. The nuclei were stained with Hoechst. Confocal
imaging demonstrated that all of the fibroblast preparations
robustly produced collagen I and fibronectin (Fig. 8a). How-
ever, 3D reconstruction of the confocal images revealed that
the hPSC-CFs, hfV-CFs, and haV-CFs produced multicell
layer cultures while the hDFs produced only monolayer cul-
tures (Fig. 8a, Supplementary Movies 1–4). The average
depths of the multilayer hPSC-CF (~40 µm) and the hfV-CF
(~44 µm) cultures were similar and greater than the haV-CF
cultures (~24 µm) and the monolayer hDF cultures (~12.5 µm)
(Fig. 8b). Although extracellular fibronectin and collagen I
were evenly distributed throughout the monolayer hDF
cultures, fibronectin was concentrated in the top layers of all
of the CF cultures in contrast to the distribution of collagen I
throughout the depth of the multilayer CF cultures (Fig. 8a).
To confirm adequate antibody penetration and ECM protein
labeling, multilayer hPSC-CF cultures were permeabilized
before immunolabeling. The permeabilized hPSC-CF culture
shows a distinct pattern of fibronectin immunolabeling with
clear intracellular fibronectin detected as well as more fibrillar
extracellular fibronectin concentrated in the upper layers
(Supplementary Fig. 16, Movie 5). Polarization of extracellular
fibronectin has been observed in other in vitro cultured cell
systems and attributed to the binding of cell produced fibro-
nectin with soluble fibronectin in the serum containing
medium to generate insoluble fibronectin concentrated at the
apical surface of the cultures49–51. Overall, these results
demonstrate that high-density culture of the fibroblast pre-
parations results in robust production of ECM proteins, but
hDFs exhibit contact inhibition and limited proliferation
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Fig. 6 Representative markers expression in CF, DF and hPSC-CM. a Histogram plot of flow cytometry analysis for vimentin. b Flow cytometry analysis of
co-labeling for PDGFRα and PDGFRβ. c Immunolabeling by antibodies for fibroblast (clone TE-7), cTnT and GATA4. d POSTN expression examined by qRT-
PCR (n= 3 technical replicates). Data are mean ± SEM. Scale bars are 100 μm. All fibroblasts samples used in the measurement are from passages 3 to 7.
The hPSCs are DF19-9-11T hiPSCs. The primary hfV-CFs are from Cell Applications, Inc. The haV-CFs are from Lonza, NHCF-V. The hDF line is from skin
biopsies from healthy donor
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b
hPSC-CF haV-CF
GO term (Category) Count P-Value GO term (Category) Count P-Value
Extracellular region part (CC) 63 3.5E-11 Extracellular region (CC) 75 1.4E-11
Extracellular region (CC) 95 8.7E-9 Extracellular region part (CC) 47 8.3E-11
Intrinsic to membrane (CC) 178 3.0E-4 Extracellular matrix (CC) 27 1.7E-10
Pattern specification process 
(BP)
36 1.6E-15 Cell adhesion (BP) 29 8.1E-6
Anterior/posterior pattern
formation (BP)
27 1.7E-15 Biological adhesion (BP) 29 8.3E-6
Sequence-specific DNA binding
(MF)
38 5.7E-7 Pattern binding (MF) 14 1.1E-6
Transcription factor activity (MF) 49 5.3E-6 Polysaccharide binding (MF) 14 1.1E-6
Cell Adhesion (BP) 48 1.4E-9 Vasculature development 
(BP) 
14 2.2E-4








































































































































































































Fig. 7 Gene expression by RNA-seq in CF compared to DF, hPSC-CM, and hPSC. a Dendrogram showing the similarity in the abundance of overall
transcripts (19,084 genes) across samples of hPSC-CF, haV-CF, hDF, hPSC-CM, and hPSC that was calculated by Euclidean distance. b Heatmap of cardiac
factors (58 genes) expression across samples of hPSC-CF, haV-CF, hDF, hPSC-CM, and hPSC organized by unsupervised cluster analysis. c Heatmap of
extracellular matrix related gene expression (98 genes) across samples of hPSC-CF, haV-CF, hDF, hPSC-CM, and hPSC presented by unsupervised cluster
analysis. d Gene ontology (GO) analysis using the functional annotation tool (DAVID Bioinformatics Resources 6.7, NIAID/NIH) for the differentially
expressed genes in hPSC-CF and haV-CF (Supplementary Data 1 and 2) with calculated p values shown. The hPSC line used for RNA-seq are DF19-9-11T
hiPSCs. The haV-CFs are from Lonza, NHCF-V, and hDFs are from 020a line. The TPM values from the RNA-seq were used for the analysis
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cultures. Furthermore, the thickness of the hPSC-CF cultures
is most similar to hfV-CF cultures and significantly greater
than the thickness of haV-CFs, which is consistent with the
hPSC-CFs exhibiting a more embryonic CF phenotype.
hPSC-CFs can transform to myofibroblasts. In the setting of
injury or disease, CFs can convert to myofibroblasts and con-
tribute to remodeling of the heart. TGFβ1 signaling is a major
stimulus for the transformation of CFs to myofibroblasts52–56.
Angiotensin II (Ang II) is another agonist that stimulates myo-
fibroblast conversion and fibrotic effects in CFs but typically not
in DFs57,58. To evaluate for myofibroblast formation induced by
both TGFβ1 and Ang II, we cultured the CFs in DMEM+10%
FBS for 48 h in the presence or absence of TGFβ1 or Ang II. The
hPSC-CFs, hfV-CFs, and haV-CFs grown with optimized fibro-
blast media exhibited low expression of α-smooth muscle actin
(SMAlow) measured by both flow cytometry and immunocy-
tochemistry. In contrast, hDFs in the confluent culture exhibited
a SMAhigh population by flow cytometry (Fig. 9, Supplementary
Fig. 17). Totally, 48 h of culture in DMEM+10% FBS led to the
emergence of a SMAhigh population in all of the CF cultures.
Furthermore, application of TGFβ1 increased the SMAhigh
population for the hPSC-CFs, hfV-CFs, and haV-CFs, and the
SMA immunolabeling showed the strong SMA expressing stress
fibers (Fig. 9). In contrast, the TGFβ1-treated hDFs showed the
overall increase of SMA expression and a larger SMAlow popu-
lation measured by flow cytometry, and the SMA immunolabel-
ing also showed the increased SMA expression in the stress fibers
(Fig. 9). The cell morphology of all the CFs from baseline con-
ditions changed significantly from spindle-shaped, small cells to
larger, more elongated cells (Fig. 9). Thus, all of the CF cultures
exhibited comparable patterns of transformation to myofibro-
blasts based on the formation of a SMAhigh population with
prominent stress fibers in response to TGFβ1. The expression
pattern of SMA also changed in hDFs in response to TGFβ1, but
the pattern of response was distinct from CFs as measured by
flow cytometry (Fig. 9). Ang II treatment induced the SMAhigh
population as observed with TGFβ1 treatment in both hPSC-CFs
and hfV-CFs, but in hDFs Ang II resulted in a decrease in the
SMAhigh population. Comparable results were observed in
response to 100 and 500 nM of Ang II (Supplementary Fig. 18).
Co-culture of hPSC-CFs effects hPSC-CM electrophysiology.
Given that CFs can influence the electrophysiological properties
of the native heart, we examined the functional impact of the co-
culture of hPSC-CFs, haV-CFs, or hDFs with hPSC-CMs
monolayers. Various ratios of fibroblasts and hPSC-CMs were
co-cultured, and representative images confirm different co-
culture proportions using immunofluorescent labeling for cTnT
(green) to identify hPSC-CMs and DAPI to label the nuclei of all
cells (Fig. 10a). In functional experiments, co-cultured mono-
layers were labeled with a membrane potential sensitive dye
(FluoVolt) to quantify the electrophysiological effects of co-
cultured fibroblasts. Time–space plots of action potential propa-
gation showed the differential impact of each fibroblast subtype
on hPSC-CM monolayer function (Fig. 10b). Cultures of 100%
hPSC-CMs showed regular spontaneous automaticity with uni-
form conduction across the cultures (Supplementary Movie 6).
Comparison of 10 and 50% fibroblast co-culture demonstrated
that the spontaneous rate was significantly faster for hPSC-CF co-
culture compared to progressively slower rates for haV-CF and
hDF co-cultures (Fig. 10b, c, Supplementary Movie 7a–c).
Impulse conduction velocity was slowed by co-cultures with 10%
of any of the fibroblast populations, although to a greater extent
in the hDF co-cultures (Fig. 10b, c, Supplementary Movie 7a–c).
Interestingly, at a ratio of 50% hPSC-CMs:50% fibroblasts, we
observed fibrillatory conduction patterns in all of the monolayer
co-cultures with hPSC-CFs (6/6) and in half of the monolayers
with haV-CFs (2/4), while the same ratio of hDFs did not induce
this arrhythmic pattern in any hPSC-CM monolayer co-cultures
tested (0/6) (Fig. 10b, c, Supplementary Movie 8a–c). Given the
different spontaneous rates observed for the various conditions,
we used field stimulation to control rate and constructed action
potential duration (APD) restitution curves for the monolayer co-
cultures. The 100% hPSC-CM and 10% hPSC-CF co-cultures
showed the shortest APD80s over the range of paced rates











































hPSC-CF hfV-CF haV-CF hDF
Fig. 8 ECM production in CF and DF cultures. a Confocal imaging of high density cultures of hPSC-CF, hfV-CF, haV-CF, and hDF immunolabeling for
extracellular collagen I and fibronectin. Z-scans are presented as projection images in the top panels and 3D reconstructions showing side views in lower
panels. Scale bars in Projection are 25 μm. Scale bars in Side view of hPSC-CF and hfV-CF are 40 μm, haV-CF are 20 μm, and hDF are 15 μm. b Thickness of
the 3D ECM scaffolds measured from 3D reconstructions of hPSC-CF (n= 8), hfV-CF (n= 9), haV-CF (n= 12), and hDF (n= 6) biological replicates. The
box plots summarize the biological replicates with the box enclosing from first to third quartile, middle square indicating mean, line in box indicating
median, and whiskers indicating outliers. *P < 0.05, one-way ANOVA with post hoc Bonferroni test
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09831-5
10 NATURE COMMUNICATIONS |         (2019) 10:2238 | https://doi.org/10.1038/s41467-019-09831-5 | www.nature.com/naturecommunications
properties of the hPSC-CM monolayers are distinctly modulated
by co-cultures with the different populations of fibroblasts.
Discussion
In the present study, we demonstrate that stage-specific activation
of Wnt and FGF signaling promotes the efficient differentiation
of hPSCs via SHFPs to CFs. The hPSC-CFs share characteristics
with native human CFs based on gene expression, cell
morphology, proliferation, ECM production, myofibroblast
transformation, and the distinct modulation of hPSC-CM elec-
trophysiology. Although cell type-specific markers for CFs are not
known, the combination of different markers present in the
hPSC-CFs including expression of PDGFRα, vimentin, FSP1, and
labeling with human fibroblast antibody along with GATA4
expression are consistent with a CF phenotype. Overall, we
conclude that this monolayer-based protocol using defined con-
ditions allows the scalable generation of SHF-derived hPSC-CFs.
In mammalian cardiac development, CFs arise from epicardium,
endocardium, and neural crest progenitor populations59. These
different fibroblast populations are concentrated in different regions
of the heart and exhibit distinct contributions to cardiac develop-
ment such as the role of endothelium-derived CFs in formation of
the cardiac cushion and ultimately cardiac valves. The three
embryological origins of CFs suggest that distinct fibroblast popu-
lations can be differentiated from hPSCs. The mesoderm-directed
differentiation protocol argues against neural crest ectoderm
derived CFs. Recent studies have described the differentiation of
hPSCs to epicardial cells that can give rise to CFs8–11. These studies
provided evidence for generation of epicardial cells based on the
expression of characteristic markers including WT1, TBX18, and
ALDH2. In the present study, we found a different pattern of gene
expression induced by FGF signaling in the developing progenitor
populations with strong evidence for a SHFP population marked by
persistent ISL1 expression, high HAND2, and transient expression
of CXCR443. The SHFPs in development can give rise to endo-
cardium via a TIE2 expressing angiogenic progenitor or a TIE2−
but ISL1+ population. The endocardium is a specialized endothelial
population commonly distinguished by the expression of
NFATc145. Our studies also did not reveal clear expression of TIE2
or NFATc1 during intermediate stages, implying the differentiation
of endocardial cells may require different signaling pathways than
the FGF signaling in the GiFGF protocol. However, given the strong
signal for SHF genes there is evidence for SHFPs and the expression
of an endothelial-to-mesenchymal transition related gene in the
GiFGF protocol, SNAI2, suggests the hPSC-CFs may have passed
through a transient endocardial intermediate. Alternatively, the
SHFPs may directly give rise to CFs as has been suggested for SHF-
derived endocardial cells in which some endocardial cells arise via
an endothelial/endocardial progenitor population and others arise
directly from SHFPs21. Consistent with our findings of the SHF-
derived hPSC-CFs, a recent study using genetic lineage tracing in
mouse models demonstrated that SHFPs in vivo can give rise to CFs
as can ESC-derived SHFPs in vitro43.
The maturity of lineages derived from hPSCs remains a critical
question in applications. For example, hPSC-CMs generated from
existing protocols are relatively immature exhibiting an embryonic/



















































































































Fig. 9 Myofibroblast transformation of CFs and DFs. Analysis of α-smooth muscle actin (SMA) expressing cells to assay for myofibroblast transformation
from hPSC-CF, hfV-CF, haV-CF, and hDF in culture. All fibroblast cultures in passages 4–6 were treated with 10 ng/ml TGFβ1 for 48 h in DMEM+10% FBS
medium. Expression of SMA was measured by both flow cytometry (upper panel) and immunolabeling (lower panel). Phase contrast images of
representative cultures are shown in the middle panel. Phase contrast images and SMA immunofluorescence images are from the same biological samples,
but not the same field of view. Scale bars are 200 μm. The hPSC-CFs are derived from DF19-9-11T hiPSCs. The hfV-CFs are from Cell Applications, Inc. The
haV-CFs are from Lonza, NHCF-V, and hDFs are from 023a line
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cell size and structure, myofilament composition, electrophysiology
and metabolism60–63. In the case of hPSC-CFs, the issue of maturity
is equally relevant. However, the CF-specific developmental mile-
stones are not well defined. We observed the hfV-CFs and hPSC-
CFs have a greater proliferative capacity than haV-CFs, a more
uniform expression of PDGFRβ, and the ability to generate thicker
3D high density cultures. Furthermore, the gene expression pattern
in the hPSC-CFs from our data is more similar to human fetal CFs
relative to adult CFs from a recently published study47. Although
these functional assays and gene expression studies are consistent
with hPSC-CFs having a more embryonic phenotype, there are
other possible explanations given the multiple sources of CFs that
may exhibit differences in their relative abundance in fetal and adult
human heart.
The ability to differentiate hPSCs to hPSC-CFs provides an
unlimited supply of CFs for a range of research in cardiac biology
and disease as well as potential clinical applications in tissue
engineering and cardiac regeneration. Nevertheless, future studies
will be needed to fully appreciate the properties of hPSC-CFs and
how they relate to the heterogeneous and incompletely defined
CFs present in the native heart.
Methods
Human PSC culture. Human iPSC line DF19-9-11T and ESC lines H1 and H9-
TnnT2-GFP were used in this study (WiCell Research Institute, cell line name:
iPS DF19-9-11T; WA01; H9-hTnnT2-pGZ-D2, respectively). hPSCs were
cultured on Matrigel (GFR, BD Biosciences) coated 6-well plates in either
mTeSR1 (DF19-9-11T, H1) medium (Stem Cell Technologies) or E8 (H9-
TnnT2-GFP) medium (ThermoFisher). Cells were passaged using Versene
solution (Invitrogen) every 4–5 days. Cells were washed with DPBS without Ca
++/Mg++ (Gibco) and incubated with 1 ml/well Versene solution at 37 °C for
3 mins. Aspirating Versene solution and adding 1 ml/well mTeSR1 or E8
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100% hPSC-CM 90/10% hPSC-CM/hPSC-CF 70/30% hPSC-CM/hPSC-CF 50/50% hPSC-CMs/hPSC-CF
90% hPSC-CMs/10%haV-CFs
Fig. 10 Effect of CFs or DFs on hPSC-CM electrophysiology in co-culture. a confocal images of different ratios hPSC-CMs and hPSC-CFs in culture together
with immunolabeling for cTnT to identify hPSC-CMs and DAPI labeling for all cells present. Scale bars are 500 µm. b Time–space plots of optical mapping
experiments. Postacquisition analysis of optical recordings was done by plotting the changes of fluorescence over time along a single line of each
monolayer, similar to a confocal line scan. Differences in the spontaneous rates of activation are evident as are altered patterns of conduction with
fibrillatory conduction observed with 50% hPSC-CF and haV-CF co-cultures with hPSC-CM. c Average spontaneous beating rate and action potential
propagation velocity for 100% hPSC-CM monolayers (n= 5) compared to co-cultures of percentages and cell types indicated (red, hPSC-CF 10% (n= 6)
and 50% (n= 4); green, haV-CF 10% (n= 5) and 50% (n= 6); blue, hDF 10% (n= 6) and 50% (n= 6)). Statistical comparisons were made between
different fibroblast populations at each fixed mixture with ANOVA and Tukey’s post hoc testing for significant differences as shown, ***P < 0.0001; **P <
0.001; and *P < 0.01. d Average action potential duration at 80% of repolarization (APD80) restitution curves generated by pacing indicated preparations
over a range of different cycle lengths and measuring optical APD80. The hPSC-CF and hPSC-CMs are derived from H9-cTnT-GFP hESCs. The haV-CFs are
from Lonza, NHCF-V, and hDFs are from skin biopsy from a healthy adult donor. Data are mean ± SEM with n representing number of separate monolayers
(biological replicates) tested
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were pellet down by centrifugation at 1000 rpm for 3 mins, and resuspended in
mTeSR1 or E8 medium, and plated in 6-well plate at the split ratio of 1:6 to
1:12. Mycoplasma tests were routinely performed (monthly) for all the cell
culture in this study.
Differentiation of hPSCs to CMs using GiWi protocol. Human PSCs were
dissociated with 1 ml/well Versene solution at 37 °C for 5 min, and seeded on
Matrigel coated 6-well plates at the density of 1.5–2.0 × 106 cells/well in
mTeSR1 medium supplemented with 10 μM ROCK inhibitor (Y-27632)
(Tocris). Cells were cultured for 5–6 days in mTeSR1 medium until reaching
100% confluence when differentiation started (day 0). At day 0, the medium
was changed to 2.5 ml RPMI+B27 without insulin (Gibco) and supplemented
with 12 µM CHIR99021 (Tocris), and cells were treated in this medium for 24 h
(day 1). After day 1, medium was changed to 3 ml RPMI+B27 without insulin
and cells were cultured in this medium for 48 h (day 1-3). Seventy-two hours
(day 3) after addition of CHIR99021, a combined medium was prepared by
collecting 1.5 ml of medium from the wells and mixing with same volume of
fresh RPMI+B27 without insulin medium and supplemented with 5 µM IWP2
(Tocris), and cells were treated with IWP2 in the medium for 48 h (day 3-5).
The medium was changed to 3 ml RPMI+B27 without insulin on day 5. On day
7 the medium was changed to RPMI+B27 with insulin (Gibco), and the cells
were fed every other day and cultured until day 20 for flow cytometry analysis.
Differentiation of hPSCs to CFs. Human PSCs were dissociated with 1 ml/well
Versene solution (Gibco) at 37 °C for 5 min, and seeded on Matrigel (GFR, BD
Biosciences) coated 6-well plates at the density of 1.5–2.0 × 106 cells/well in
mTeSR1 medium supplemented with 10 μM ROCK inhibitor (Y-27632) (Tocris).
Cells were cultured for 5–6 days in mTeSR1 medium with medium changes daily
until they reached 100% confluence when differentiation started (day 0). At day 0,
the medium was changed to 2.5 ml RPMI+B27 without insulin and supplemented
with 12 µM CHIR99021 (Tocris) and cells were treated in this medium for 24 h
(day 1). After day 1, the medium was changed to 2.5 ml RPMI+B27 without
insulin (Gibco) and cells were cultured in this medium for 24 h (day 2). After day 2
but within 24 h (before day 3), the medium was changed to 2.5 ml of the CFBM
medium (Supplementary Table 1) supplemented with 75 ng/ml bFGF (WiCell
Research Institute). Cells were fed with CFBM+75 ng/ml bFGF every other day
until day 20 when they were used for flow cytometry analysis and passaged.
Culture of human CFs and DFs. The hPSC-differentiated CFs (hPSC-CFs), pri-
mary human fetal ventricular cardiac fibroblasts (hfV-CFs, Cell Applications, Inc.,
cryopreserved HCF, fetal: 306-05f, lot 2666) and adult ventricular cardiac fibro-
blasts (haV-CFs, Lonza, NHCF-V, CC-2904, lot 0000401462) and primary dermal
fibroblasts (hDFs, healthy donors, 020a and 023a lines, generated with informed
consent as approved by UW-Madison Health Science IRB, protocol H-2008-0250)
were used in this study. hPSC-CFs at 20 days of differentiation were dissociated
with 0.05% Trypsin-EDTA (Gibco) and plated in 6-well noncoding plastic plates at
the density of 300,000 cells/well in 2 ml of FibroGRO medium (Millipore EMD,
SCMF001) plus 2% FBS (Gibco). The hPSC-CFs were fed every other day with 2 ml
FibroGRO+2% FBS medium and passaged every 4–6 days using 0.05% Trypsin-
EDTA. The plating density for passaging hPSC-CFs was 5800 cells/cm2. The hfV-
CFs were thawed at the plating density of 7000 cells/cm2 in the Human CF Growth
Medium (CFGM, Cell Applications, Inc., 316–500) and the haV-CFs were thawed
at the plating density of 3500 cells/cm2 in FGM-3 medium (Lonza, CC-4526) in
noncoding plastic T75 flasks. The media were changed the next day after thaw and
cells were fed every other day afterward. The hfV-CFs were cultured in both the
CFGM and FibroGRO+2% FBS media and were passaged every 4–6 days using
0.05% Trypsin-EDTA. The haV-CFs were cultured with the FGM-3 medium and
were passaged every 4–8 days using 0.05% Trypsin-EDTA. The subsequent plating
density for passaging after thaw was 5800 and 3500 cells/cm2 for hfV-CFs and haV-
CFs, respectively. The primary hDFs were thawed in DMEM high glucose with
GlutaMAX supplement (Gibco 10566-016) plus 10% FBS (Gibco 10437) in non-
coding plastic T75 flasks at the density of 1900 cells/cm2. The hDFs were cultured
in the DMEM high glucose+10% FBS with medium change every other day and
were passaged every 6–8 days using 0.05% Trypsin-EDTA. The subsequent plating
density for passaging hDFs was 1900 cells/cm2.
All fibroblasts were cryopreserved in 50% DMEM high glucose with GlutaMAX
supplement (Gibco 10566-016), 40% FBS and 10% DMSO.
Flow cytometry. Cells were dissociated by incubation with 0.25% trypsin-EDTA
(Gibco) plus 2% chick serum (Sigma) for 5 min at 37 °C. Cells were vortexed to
disrupt the aggregates followed by neutralization by adding equal volume of EB20
medium41. Cells were counted and 0.5–1 million of cells were used for labeling. For
labeling surface markers, cells were labeled either before, or after fixed in 1%
paraformaldehyde at 37 °C water bath for 10 min in the dark. For labeling intra-
cellular markers, cells were fixed in 1% paraformaldehyde and permeabilized in ice-
cold 90% methanol for 30 min on ice. Cells were washed once in FACS buffer
(DPBS without Ca++/Mg++, 0.5% bovine serum albumin (BSA), 0.1% NaN3),
centrifuged and resuspended in about 50 μl FACS buffer with (for intracellular
markers) or without 0.1% Triton X-100 (Sigma). For labeling surface markers,
appropriate amount of the conjugated antibodies according to the manufacturer’s
instruction were added to the cells in FACS buffer to make the final volume of 100
μl with FACS buffer, and incubated at room temperature in dark for 30 min. Cells
were washed once with 3 ml FACS buffer and resuspended in 300–500 μl FACS
buffer for analysis. For labeling intracellular markers, the primary antibody was
diluted in 50 μl /sample FACS buffer plus 0.1% Triton X-100 and aliquoted to each
sample for a total sample volume of 100 μl. Samples were incubated with the
primary antibodies overnight at 4 °C. Please refer to Supplementary Table 2 for the
primary antibodies used in this study. For the secondary antibody labeling, cells
were washed once with 3 ml FACS buffer plus 0.1% Triton X-100 after the primary
antibody labeling, centrifuged, and supernatant discarded leaving ~50 μl. Second-
ary antibody specific to the primary IgG isotype was diluted in FACS buffer plus
0.1% Triton X-100 in a final sample volume of 100 μl at 1:1000 dilution. Samples
were incubated at room temperature in dark for 30 min, washed in FACS buffer
and resuspended in 300–500 μl FACS buffer for analysis. Data were collected on a
FACSCalibur (Beckton Dickinson) and Attune Nxt (ThermoFisher) flow cyt-
ometers and analyzed using FlowJo.
Immunocytochemistry. For imaging with EVOS microscope (Life Technologies),
cells were cultured in either 6-well or 12-well plates. Cells were fixed with 4%
paraformaldehyde for 15 min at room temperature, and permeabilized in 0.2%
Triton X-100 (Sigma) for 0.5–1 h at room temperature. After fix and permeabili-
zation, cells were blocked with 5% nonfat dry milk (Bio-Rad) in 0.2% Triton X-100
solution and incubated for 1.5–2 h at room temperature on a rotator followed by
two washes with DPBS. Primary antibodies (Supplementary Table 2) were added in
1% BSA in DPBS solution with 0.1% Triton X-100, and incubated overnight at
4 °C. Cells were washed with 0.2% Tween 20 in DPBS twice and DPBS twice.
Secondary antibody specific to the primary IgG isotype were diluted (1:1000) in the
same solution as the primary antibodies and incubated at room temperature for 1 h
in dark on a rotator. Cells were washed with 0.2% Tween 20 in DPBS twice and
DPBS twice. Nuclei were labeled with Hoechst or DAPI.
Quantitative RT-PCR. Cell samples were collected using 0.25% trypsin–EDTA
(Invitrogen) to remove the cells from cell culture plates. Total RNA was purified
using QIAGEN RNeasy® Mini kit. Any genomic DNA contamination was removed
by RNase-Free DNase Set (QIAGEN) with the RNeasy columns or by DNase I
(Invitrogen) treatment for 15 min at room temperature. 500 ng of total RNA was
used for Oligo (dT)20—primed reverse transcription using SuperScript™ III First-
Strand Synthesis System (Invitrogen). Quantitative RT-PCR was performed using
Taqman PCR Master Mix and Gene Expression Assays (Applied Biosystems,
Supplementary Table 3) in triplicate for each sample and each gene. 0.5 μl of cDNA
from RT reaction was added as template for each Q-PCR reaction. The expression
of genes of interest was normalized to GAPDH.
RNA-seq and data analysis. Cell samples were collected using 0.25%
trypsin–EDTA (Invitrogen) to remove the cells from cell culture plates. Total RNA
was purified using QIAGEN RNeasy® Mini kit. Possible genomic DNA con-
tamination was removed by RNase-Free DNase Set (QIAGEN) with the RNeasy
columns. Duplicates for each sample were submitted for RNA-seq. Total RNA was
qualified with the Life Technologies Qubit fluourometer (Q32857) and Agilent
Bioanalyzer (G2940CA). One-hundred nanograms of total RNA was used to
prepare indexed cDNA libraries with the Ligation Mediated Sequencing (LM-Seq)
protocol64. Final indexed cDNA libraries were pooled with thirty uniquely indexed
LM-Seq cDNA libraries per lane and sequenced on an Illumina HiSeq 2500 with a
single 51 bp read and a 10 bp index read. Base-calling and demultiplexing were
performed using Casava (v1.8.2). Sequences were filtered and trimmed to remove
low quality reads, adapters, and other sequencing artifacts. The remaining reads
were aligned to 19084 Refseq genes extracted from the Illumina iGenomes refer-
ence, selecting only those with “NM_” annotations. Bowtie (v 0.12.9) was used for
alignment, allowing two mismatches in a 28 bp seed65. Reads with more than 200
alignments were excluded from further analysis. RSEM (v1.2.3) was used to esti-
mate isoform and relative gene expression levels (transcripts per million or “TPM”)
66. Genes for specific functional groups were selected by searching online tool
AmiGO2 (http://amigo.geneontology.org) using key words and manually con-
firmed. Heatmaps were generated using pheatmap_1.0.8 in R version 3.2.3. The
similarity heatmap showed the Euclidean distances between samples which were
calculated using R dist function on normalized read counts.
ECM production and confocal imaging. Confluent hPSC-CFs, primary hfV-CFs
and haV-CFs, and hDFs were dissociated with TrypLE Express (Gibco) and seeded
in μ-Dish 35 mm ibidi dish (Cat# 81156) at the density of 1.25 × 106 cells/dish.
Cells were grown for 10 days with medium change every other day. hPSC-CFs and
primary hfV-CFs were grown with FibroGRO medium (Millipore EMD,
SCMF001) plus 2% FBS Gibco, primary haV-CFs were grown in FGM-3 media
(Lonza), and hDFs were grown in DMEM high glucose with GlutaMAX supple-
ment (Gibco) plus 10% FBS (Gibco) medium. On day 10, cells were fixed with 4%
paraformaldehyde for 15 min at room temperature, and stored in DPBS at 4 °C.
The ECM proteins including collagen and fibronectin were co-labeled with anti-
COL1A (COL-1) (Santa Crutz Biotechnology, sc-59772) and anti-Fibronectin
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(A-11) (Santa Crutz Biotechnology, sc-271089) antibodies without permeabiliza-
tion of the cells to examine the ECM using the immunolabeling protocol in the
‘Immunocytochemistry’ section. The cellular fibronectin and SMA expression were
examined in the permeabilized cells and the antibodies were co-labeled using
the same immunolabeling protocol in the “Immunocytochemistry” section. Cells
were imaged using the confocal microscope (Leica TCS SP5 system).
Co-cultures of hPSC-CMs and hPSC-CFs, haV-CFs or hDFs. hPSC-CMs were
cultured with hPSC-CFs, haV-CFs, or hDFs at varying percentages: 100, 90, 70, 50,
or 0%. These co-cultures were plated at a density of 250,000 cells per 200 µl drop of
EB20 medium (80% DMEM/F12, 0.1 mmol/L nonessential amino acids, 1 mmol/L
L-glutamine, 0.1 mmol/L β-mercaptoethanol, 20% FBS and 10 μmol/L blebbistatin)
on 18 × 18 mm pieces of polydimethylsiloxane silicone sheeting (SMI; Saginaw,
MI) coated with Matrigel (500 μg/mL, Corning) and grown for 3 days kept at 37 °C
in 5% CO267. At this point the media was changed to RPMI (Gibco) supplemented
with B27 (Gibco) and replaced every 2 days for 4 days prior to experimentation.
Optical mapping. Optical action potentials and time–space plots were recorded
using FluoVolt™ membrane potential probe (F10488, Life Technologies)67–70.
After a 30 minute incubation period, monolayers were transferred to Hank’s
balanced salt solution (HBSS with calcium and magnesium, Gibco) for optical
mapping recording and kept at 37°C for the duration of the experiment. All
monolayers containing hPSC-CMs displayed spontaneous pacemaker activity
which was recorded using a CCD camera (Red-Shirt Little Joe, Scimeasure,
Decatur, GA, 80 × 80 pixels) with the appropriate emission filters and LED
illumination68. A total of 10 s movies were taken at 200 fps (LabWindows
Acquisition, National Instruments, Austin, TX, USA) which were amplified,
filtered and digitized for offline analysis. Briefly, time sequence plot graphs of
fluorescence intensity over time were generated from average action potentials
and used for calculation of action potential duration after signal filtering. In
addition, optical mapping movies were processed with Scroll to generate acti-
vation maps and calculation of conduction velocity after providing spatial
calibration to the software. Repetitive stimuli (duration, 5 ms; strength, twice
diastolic threshold) was applied by field stimulation using silver electrodes.
Monolayers were paced faster than the spontaneous beating rate, which was
different depending on the co-culture with hPSC-CFs, haV-CFs, or hDFs
(Fig. 10c, d). Stimulation frequency ranged from 1000 to 285.7 ms cycle length.
Statistics. Sample size varies and was determined based on anticipated scatter of
the data, but formal power calculations were not done given the lack of previous
comparable datasets from which to estimate variance. Data are presented as mean
± standard error of the mean. Technical and biological replicates are as indicated
for each dataset. For datasets with normal distributions, statistical significance was
determined by Student’s t test for two groups or one-way ANOVA for multiple
groups with post hoc test using Bonferroni and Tukey methods. Statistical analysis
was performed using Origin, v9, P < 0.05 was considered statistically significant.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The RNA-seq data for this study are deposited in GEO with the accession code
GSE126260. All other relevant data generated in this manuscript that support the
findings of this study are available upon request from the authors.
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